Transcript
((Sara M. Tinsley, Ph.D., ARNP, AOCN))
If a secondary AML patient is an appropriate candidate for transplant, we set transplant as a goal from the beginning and go for that.
We usually prepare for transplant as the patient responds to therapy, when the blasts are less than 5% per bone marrow biopsy and there are no other indicators of disease.
With a longer time to recovery of platelet counts with VYXEOS, we generally just focus on the blast count when assessing readiness for transplant.
It's important to try to get the patient to transplant as quickly as possible while they are in remission, so knowing the goal up front is helpful.
Factors that indicate readiness for transplant will vary by institution.
INDICATION
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION